About this trial
Among winter respiratory viruses, influenza is the most common and therefore responsible for the highest mortality, but parainfluenza and RSV viruses have an even higher risk of mortality (1.6 to 1.9 times), this toll being paid mainly by the elderly and co-morbid population. Futhermore, SARS-Cov2 will probably become endemic and/or epidemic with the same targets of fragile patients. These viral infections are serious, however a bacterial co-infection worsens the prognosis even more: excess risk of mortality = 2.6, 95% CI \[1.9-3.7\].
Although rare, these co-infections are the subject of a prescription of antibiotics in more than 50% of influenza infections or other serious viral infections. Mainly due to this excess risk of mortality associated with the difficulty of diagnosing these co-infections.
Proper antibiotic use requires preventing this misuse and its harmful consequences in the short and long term at all costs. It is therefore imperative to have solid (grade A) evidence showing that antibiotic therapy in viral infections is not only futile but also potentially harmful.
Eligibility criteria
Qualifiers
Patients ≥ 65 years affiliated to a social security scheme
hyperthermia >38°C,
hyperleukocytosis ≥12000 or ≤4000,
purulent aspirations/sputum,
Disqualifiers
Hospitalization planned for < 48 hours or transfer planned to another center within 7 days
Patient in septic shock,
Febrile aplasia
Absence of diagnostic microbiological sampling (> 48 hours after admission)
Trial design
Treatments tested in this trial
- antibiotic withdrawal
- Antibiotics
Treatment groups
Sponsors and collaborators
Centre Hospitalier Universitaire, Amiens
Lead sponsor
University Hospital, Rouen
Collaborator
Centre Hospitalier de Beauvais
Collaborator
University Hospital, Caen
Collaborator
Hôpital Les Bateliers, CHU de Lille
Collaborator
Centre Hospitalier Roubaix
Collaborator
CH SOISSONS
Collaborator
Tourcoing Hospital
Collaborator